Open-label, Single-center, Single-arm Futility Trial Evaluating the Combination of Oral Hydroxychloroquine 200mg BID and Indapamide 2.5mg OD for Reducing Progression of Disability in People With Secondary Progressive Multiple Sclerosis (SPMS) Open-label, Single-center, Single-arm Futility Trial Evaluating the Combination of Oral Hydroxychlor ...